Global Gliquidone (CAS 33342-05-1) Market Size By Type (Glequinone Tablets, Glequinone Sustained Release Tablets), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forec...

The Global Gliquidone (CAS 33342-05-1) Market was valued at USD 312.4 million in 2023 and is projected to reach USD 482.1 million by 2031, growing at a CAGR of 5.7% during the forecast period (2023–2031). Gliquidone, a second-generation sulfonylurea, is primarily used in the treatment of type 2 diabetes mellitus due to its ability to stimulate insulin secretion. The market growth is driven by rising diabetes prevalence, expanding geriatric population, and increasing demand for cost-effective oral antidiabetic medications. Additionally, its minimal renal excretion makes it particularly suitable for elderly patients and those with renal impairment, further boosting its clinical preference.

Drivers:

Rising Prevalence of Type 2 Diabetes:

The global rise in sedentary lifestyles, obesity, and unhealthy dietary habits has led to a surge in type 2 diabetes cases. Gliquidone remains a popular therapeutic option due to its proven efficacy and affordability, especially in emerging economies.

Increasing Geriatric Population:

Older adults, who are more susceptible to diabetes and renal complications, benefit from Gliquidone’s low renal excretion profile. This demographic trend significantly fuels the demand.

Growth in Generic Drug Production:

The patent expiration and increasing approvals for generic versions of Gliquidone are making it more accessible, driving wider adoption across price-sensitive markets.

Restraints:

Emergence of Newer Antidiabetic Therapies:

The availability of newer drug classes such as DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors offers greater glycemic control with fewer side effects, potentially impacting Gliquidone’s market share.

Risk of Hypoglycemia:

Gliquidone, like other sulfonylureas, carries a risk of hypoglycemia, especially when combined with other glucose-lowering agents, which can limit its usage among certain patient groups.

Opportunity:

Expansion in Low and Middle-Income Countries:

The growing diabetes burden in Asia-Pacific, Africa, and Latin America presents substantial opportunities. Government initiatives to make antidiabetic drugs affordable and accessible are opening new markets for Gliquidone.

Integration into Combination Therapies:

The potential for Gliquidone to be used in fixed-dose combination therapies with metformin or other oral antidiabetics offers a lucrative pathway for innovation and market expansion.

Market by System Type Insights:

Based on system type, the Tablet Formulation segment held the largest market share in 2023. Oral administration remains the most preferred route due to ease of use and high patient compliance. Sustained-release and film-coated variants are gaining traction for offering better tolerability and extended efficacy.

Market by End-use Insights:

Hospitals were the largest end-users in 2023, driven by increasing inpatient diabetes treatment cases and reliance on standard treatment protocols involving sulfonylureas. Pharmacies are anticipated to grow at the fastest pace, owing to the rising trend of outpatient diabetes management and home-based care.

Market by Regional Insights:

Asia-Pacific dominated the market in 2023, accounting for the highest share due to high diabetes prevalence, growing healthcare infrastructure, and the dominance of generic pharmaceutical production. Europe and North America follow, supported by advanced healthcare systems and a focus on cost-effective treatments for elderly patients. Latin America and MEA are expected to witness the highest CAGR due to rapid urbanization and expanding diabetic population bases.

Competitive Scenario:

Key players in the Global Gliquidone Market include Sanofi S.A., Merck KGaA, Chongqing Huapont Pharmaceutical, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Zhejiang Zhenyuan Pharmaceutical Co., Ltd., and Abbott Laboratories. Companies are focusing on expanding generic offerings, obtaining regulatory approvals, and exploring strategic partnerships to enhance their distribution networks in underserved regions.

Key Developments:

In 2023, Jiangsu Hansoh Pharmaceutical launched a new sustained-release formulation of Gliquidone targeting elderly diabetic populations in China.

In 2024, Abbott Laboratories expanded its generics portfolio by acquiring a regional Asian manufacturer of Gliquidone.

In 2025, Merck KGaA collaborated with local pharmaceutical firms in Latin America to increase affordable access to oral antidiabetic drugs.

Scope of Work – Global Gliquidone (CAS 33342-05-1) Market

FAQs:

1) What is the current market size of the Global Gliquidone (CAS 33342-05-1) Market?

The Global Gliquidone Market was valued at USD 312.4 million in 2023.

2) What is the major growth driver of the Global Gliquidone (CAS 33342-05-1) Market?

The rising prevalence of type 2 diabetes and increasing geriatric population are the primary growth drivers.

3) Which is the largest region during the forecast period in the Global Gliquidone (CAS 33342-05-1) Market?

Asia-Pacific held the largest market share in 2023 and is expected to continue leading throughout the forecast period.

4) Which segment accounted for the largest market share in Global Gliquidone (CAS 33342-05-1) Market?

The Tablet Formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Gliquidone (CAS 33342-05-1) Market?

Sanofi S.A., Merck KGaA, Abbott Laboratories, Chongqing Huapont Pharmaceutical, and Jiangsu Hansoh Pharmaceutical are among the key players.